Your browser doesn't support javascript.
loading
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Hollebecque, Antoine; Chung, Hyun C; de Miguel, Maria J; Italiano, Antoine; Machiels, Jean-Pascal; Lin, Chia-Chi; Dhani, Neesha C; Peeters, Marc; Moreno, Victor; Su, Wu-Chou; Chow, Kay Hoong; Galvao, Violeta R; Carlsen, Michelle; Yu, Danni; Szpurka, Anna M; Zhao, Yumin; Schmidt, Shelly L; Gandhi, Leena; Xu, Xiaojian; Bang, Yung-Jue.
Affiliation
  • Hollebecque A; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France. antoine.hollebecque@gustaveroussy.fr.
  • Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of South Korea.
  • de Miguel MJ; START Madrid, HM Sanchinarro Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Italiano A; Institut Bergonié, Bordeaux, France.
  • Machiels JP; Department of Medical Oncology, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Institut Roi Albert II, Université catholique de Louvain, Brussels, Belgium.
  • Lin CC; National Taiwan University Hospital, Taipei, Taiwan.
  • Dhani NC; Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.
  • Peeters M; Department of Oncology, Antwerp University Hospital, Edegem, Belgium.
  • Moreno V; START Madrid FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain.
  • Su WC; National Cheng Kung University Hospital, Taiwan.
  • Chow KH; Eli Lilly and Company, Windlesham, Surrey, United Kingdom.
  • Galvao VR; Eli Lilly and Company, Indianapolis, Indiana.
  • Carlsen M; Eli Lilly and Company, Indianapolis, Indiana.
  • Yu D; Eli Lilly and Company, Indianapolis, Indiana.
  • Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana.
  • Zhao Y; Eli Lilly and Company, Indianapolis, Indiana.
  • Schmidt SL; Eli Lilly and Company, Indianapolis, Indiana.
  • Gandhi L; Eli Lilly and Company, New York, New York.
  • Xu X; Eli Lilly and Company, New York, New York.
  • Bang YJ; Seoul National University College of Medicine, Seoul, Republic of South Korea.
Clin Cancer Res ; 27(23): 6393-6404, 2021 12 01.
Article in En | MEDLINE | ID: mdl-34465599
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7-H1 Antigen / Neoplasms Limits: Humans Language: En Journal: Clin Cancer Res Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7-H1 Antigen / Neoplasms Limits: Humans Language: En Journal: Clin Cancer Res Year: 2021 Document type: Article